<DOC>
	<DOCNO>NCT00295971</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy total body irradiation donor bone marrow transplant peripheral blood stem cell transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving antithymocyte globulin remove T cell donor cell transplant may stop happen . PURPOSE : This phase I trial study side effect best dose donor T cell antithymocyte globulin give together chemotherapy total-body irradiation treat young patient undergo T-cell deplete donor stem cell transplant myelodysplastic syndrome , leukemia , bone marrow failure syndrome , severe immunodeficiency disease .</brief_summary>
	<brief_title>Donor Stem Cell Transplant Treating Young Patients With Myelodysplastic Syndrome , Leukemia , Bone Marrow Failure Syndrome , Severe Immunodeficiency Disease</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy toxicity stem cell-enriched , T-cell-depleted , haplocompatible allogeneic hematopoietic stem cell transplantation child high-risk myelodysplastic syndrome , high-risk leukemia , severe acquire congenital cytopenia , primary immunodeficiency disease . - Determine toxicity fludarabine thiotepa-containing regimen combination low dose antithymocyte globulin patient . - Determine engraftment rate patient treat regimen . - Define T-cell reconstitution patient . - Determine toxicity effect administer stem cell T-cell boost transplantation hematopoiesis immune reconstitution patient . OUTLINE : This dose-escalation study donor CD3+ cell antithymocyte globulin ( ATG ) . - Cytoreductive regimen : Patients undergo total body irradiation twice daily day -9 -7 . Patients also receive fludarabine IV day -6 -2 , thiotepa IV every 12 hour day -6 , ATG IV day -5 -2 . - Transplantation : Patients undergo CD34-enriched , T-cell-depleted , haplocompatible allogeneic peripheral blood stem cell bone marrow transplantation day 0 . - Donor T-cell infusion : Patients active graft-vs-host disease evidence engraftment low absolute CD34+ lymphocyte count 12 week post transplant may receive donor CD3+ cell 4-week interval . - Donor stem cell boost : Patients engraftment either cytokine transfusion dependent 12 week post transplant may receive boost donor CD34+ cell . Cohorts 3-6 patient receive escalate dos donor CD3+ cell ATG optimum determine . The optimum dose define dose engraftment T-cell recovery occur , without dose-limiting toxicity , ≥ 5 6 patient . After completion study treatment , patient follow periodically 5 year every 5 year thereafter . PROJECTED ACCRUAL : A total 21 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one following : Acute lymphoblastic leukemia ≥ 2nd remission delay remission induction Highrisk myelodysplastic syndrome Refractory anemia excess blast ( RAEB ) RAEB transformation Chronic myelogenous leukemia second chronic phase No accelerate phase ( &gt; 5 % blast marrow ) Juvenile myelomonocytic leukemia Acute nonlymphoblastic leukemia &gt; 1st remission induction failure &lt; 30 % blast marrow Severe aplastic anemia , define absolute neutrophil count &lt; 500/mm^3 platelet and/or red blood cell transfusion dependent Unresponsive immunosuppressive therapy No Fanconi 's anemia Congenital marrow aplasias unresponsive cytokine transfusion dependent Inherited immunodeficiency disease involve neutrophil lymphocyte , include follow : ChediakHigashi disease WiskottAldrich syndrome Combined immunodeficiency disease ( Nezelof 's ) Hyper IgM syndrome No relapsed disease Haplocompatible related donor , include parent , cousin , aunt , uncle , grandparent , halfsibling , sibling ( ≥ 12 year age ) , available 2 3 HLA antigen mismatch At least 3 HLA antigen genotypic match No closely match related unrelated donor available sufficient time transplant PATIENT CHARACTERISTICS : No active hepatitis cytomegalovirus infection Cardiac ejection fraction ≥ 30 % Creatinine clearance ≥ 70 mL/min DLCO ≥ 70 % predict No active infection No HIV positivity PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>severe congenital neutropenia</keyword>
	<keyword>congenital amegakaryocytic thrombocytopenia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>